A reality check for overdiagnosis estimates associated with breast cancer screening

Ruth Etzioni, Jing Xia, Rebecca Hubbard, Noel S. Weiss, Roman Gulati

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The frequency of overdiagnosis associated with breast cancer screening is a topic of controversy. Published estimates vary widely, but identifying which estimates are reliable is challenging. In this article we present an approach that provides a check on these estimates. Our approach leverages the close link between overdiagnosis and lead time by identifying the average lead time most consistent with a given overdiagnosis frequency. We consider a high-profile study that suggested that 31% of breast cancers diagnosed in the United States in 2008 were overdiagnosed and show that this corresponds to an average lead time of about nine years among localized cases. Comparing this estimate with the average lead time for invasive, screen-detected breast cancers of 40 months, around which there is a relative consensus, suggests the published estimate of overdiagnosis is excessive. This approach provides a novel way to appraise estimates of overdiagnosis given knowledge of disease natural history.

Original languageEnglish (US)
Article numberdju315
JournalJournal of the National Cancer Institute
Volume106
Issue number12
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Early Detection of Cancer
Breast Neoplasms
Natural History
Medical Overuse

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A reality check for overdiagnosis estimates associated with breast cancer screening. / Etzioni, Ruth; Xia, Jing; Hubbard, Rebecca; Weiss, Noel S.; Gulati, Roman.

In: Journal of the National Cancer Institute, Vol. 106, No. 12, dju315, 01.01.2014.

Research output: Contribution to journalArticle

Etzioni, Ruth ; Xia, Jing ; Hubbard, Rebecca ; Weiss, Noel S. ; Gulati, Roman. / A reality check for overdiagnosis estimates associated with breast cancer screening. In: Journal of the National Cancer Institute. 2014 ; Vol. 106, No. 12.
@article{a623d9307e1b4fec947a602ef2c97ddd,
title = "A reality check for overdiagnosis estimates associated with breast cancer screening",
abstract = "The frequency of overdiagnosis associated with breast cancer screening is a topic of controversy. Published estimates vary widely, but identifying which estimates are reliable is challenging. In this article we present an approach that provides a check on these estimates. Our approach leverages the close link between overdiagnosis and lead time by identifying the average lead time most consistent with a given overdiagnosis frequency. We consider a high-profile study that suggested that 31{\%} of breast cancers diagnosed in the United States in 2008 were overdiagnosed and show that this corresponds to an average lead time of about nine years among localized cases. Comparing this estimate with the average lead time for invasive, screen-detected breast cancers of 40 months, around which there is a relative consensus, suggests the published estimate of overdiagnosis is excessive. This approach provides a novel way to appraise estimates of overdiagnosis given knowledge of disease natural history.",
author = "Ruth Etzioni and Jing Xia and Rebecca Hubbard and Weiss, {Noel S.} and Roman Gulati",
year = "2014",
month = "1",
day = "1",
doi = "10.1093/jnci/dju315",
language = "English (US)",
volume = "106",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - A reality check for overdiagnosis estimates associated with breast cancer screening

AU - Etzioni, Ruth

AU - Xia, Jing

AU - Hubbard, Rebecca

AU - Weiss, Noel S.

AU - Gulati, Roman

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The frequency of overdiagnosis associated with breast cancer screening is a topic of controversy. Published estimates vary widely, but identifying which estimates are reliable is challenging. In this article we present an approach that provides a check on these estimates. Our approach leverages the close link between overdiagnosis and lead time by identifying the average lead time most consistent with a given overdiagnosis frequency. We consider a high-profile study that suggested that 31% of breast cancers diagnosed in the United States in 2008 were overdiagnosed and show that this corresponds to an average lead time of about nine years among localized cases. Comparing this estimate with the average lead time for invasive, screen-detected breast cancers of 40 months, around which there is a relative consensus, suggests the published estimate of overdiagnosis is excessive. This approach provides a novel way to appraise estimates of overdiagnosis given knowledge of disease natural history.

AB - The frequency of overdiagnosis associated with breast cancer screening is a topic of controversy. Published estimates vary widely, but identifying which estimates are reliable is challenging. In this article we present an approach that provides a check on these estimates. Our approach leverages the close link between overdiagnosis and lead time by identifying the average lead time most consistent with a given overdiagnosis frequency. We consider a high-profile study that suggested that 31% of breast cancers diagnosed in the United States in 2008 were overdiagnosed and show that this corresponds to an average lead time of about nine years among localized cases. Comparing this estimate with the average lead time for invasive, screen-detected breast cancers of 40 months, around which there is a relative consensus, suggests the published estimate of overdiagnosis is excessive. This approach provides a novel way to appraise estimates of overdiagnosis given knowledge of disease natural history.

UR - http://www.scopus.com/inward/record.url?scp=84922394464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922394464&partnerID=8YFLogxK

U2 - 10.1093/jnci/dju315

DO - 10.1093/jnci/dju315

M3 - Article

VL - 106

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

M1 - dju315

ER -